ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 26 of 374 for:    Recruiting, Not yet recruiting, Available Studies | "weight loss"

Obesity Surgery and Kidney Transplant for Patients With Obesity and Renal Failure

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02128802
Recruitment Status : Recruiting
First Posted : May 1, 2014
Last Update Posted : February 28, 2018
Sponsor:
Information provided by (Responsible Party):
Seth Karp, Vanderbilt University

Brief Summary:
Gastric Bypass followed by renal transplantation is superior to medical management followed by renal transplant for patients with severe obesity and renal failure.

Condition or disease Intervention/treatment Phase
Severe Obesity Renal Failure Procedure: Gastric Bypass Other: Weight Loss Program Not Applicable

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 75 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Weight Reduction Surgery Followed by Kidney Transplantation for Patients With Class III Obesity and Renal Failure
Study Start Date : April 2014
Estimated Primary Completion Date : April 2019
Estimated Study Completion Date : April 2019

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Surgical Gastric Bypass
Patients will undergo surgical gastric bypass according to standard institutional protocols
Procedure: Gastric Bypass
Experimental: Medical Weight Loss Management
Patients will receive best practices medical management for weight loss under current institutional protocols
Other: Weight Loss Program



Primary Outcome Measures :
  1. Ability to reach medical suitability for renal transplant within 18 months after initiating treatment and the change and trajectory of health-related quality of life (HRQOL) [ Time Frame: 18 months ]
    Outcomes will be measured based on weight loss and a variety of validated surveys and questionnaires to measure HRQOL


Secondary Outcome Measures :
  1. All-cause mortality [ Time Frame: 5 years ]
    Number of patients who die from any cause

  2. Weight loss [ Time Frame: 5 years ]
    Amount of weight lost at various points over the study period

  3. Surgical outcomes [ Time Frame: 5 years ]
    Incidence of surgical complications including but not limited to leak rate, stricture rate, pulmonary embolism, and infection.

  4. Development or regression of diabetes [ Time Frame: 5 years ]
    Including but not limited to start of stop of insulin therapy, amount of insulin required, and start or stop of or cal medications.

  5. Development or regression of other comorbidities [ Time Frame: 5 years ]
    Development or regression of other diseases including but not limited to hypertension, coronary artery disease, and skin infections.

  6. Health care utilization [ Time Frame: 5 years ]
    This outcome measure includes but is not limited to the amount of money spent on health care, total hospitalization, days of hospitalization, and procedures required.

  7. Nutritional status [ Time Frame: 5 years ]
    This outcome includes but is not limited to measures of albumin, pre-albumin, and caloric intake.

  8. Hormonal and metabolic status [ Time Frame: 5 years ]
    This outcome includes but is not limited to measurement of protein catabolism, creatinine clearance, and serum prealbumin. In addition, protein and iron metabolism will be measured using serum albumin, transferrin and ferritin. Glucose metabolism will be measured by glucose and insulin levels. regression of the disease. Lipid metabolism will be assessed with triglyceride levels, very-low density lipoproteins, and cholesterol. Micronutrient levels will be measured with vitamin D, thiamin, B12, and folate.


Other Outcome Measures:
  1. Prograf dosing [ Time Frame: 5 years ]
    This outcome will assess the amount of prograf required for therapeutic levels



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 59 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Body mass index 40-55 kg/m2
  • Age less than 60 years
  • Available support person
  • Adequate insurance
  • All other criteria required for renal transplantation

Exclusion Criteria:

  • Schizophrenia
  • Bipolar disorder
  • Crohn's disease
  • Human Immunodeficiency Virus
  • Cirrhosis
  • Prior weight loss surgery
  • Prior mesh hernia repair
  • Prior anti-reflux surgery
  • Inability to walk 200 feet
  • Significant coronary disease
  • Significant lung disease - Fixed expiratory volume 1 less than 75% or on oxygen
  • Addiction to alcohol or drugs
  • Inability to quit smoking
  • Jehovah's witness
  • Non-compliance with dialysis regimen
  • Previous renal transplant
  • Non-English speaking

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02128802


Contacts
Contact: Seth Karp, MD 6159368989 seth.karp@vanderbilt.edu
Contact: Andrea W Reed, MS (615) 875-1728 andrea.w.reed@vanderbilt.edu

Locations
United States, Tennessee
Vanderbilt University Medical Center Recruiting
Nashville, Tennessee, United States, 37232
Principal Investigator: Seth Karp, MD         
Sponsors and Collaborators
Vanderbilt University

Responsible Party: Seth Karp, Professor, Vanderbilt University
ClinicalTrials.gov Identifier: NCT02128802     History of Changes
Other Study ID Numbers: 130912
First Posted: May 1, 2014    Key Record Dates
Last Update Posted: February 28, 2018
Last Verified: May 2017

Keywords provided by Seth Karp, Vanderbilt University:
Obesity
Renal failure
Gastric bypass

Additional relevant MeSH terms:
Obesity
Renal Insufficiency
Obesity, Morbid
Overnutrition
Nutrition Disorders
Overweight
Body Weight
Signs and Symptoms
Kidney Diseases
Urologic Diseases